A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of a Single Intravenous (IV) Infusion of TRP-8803 (psilocin) in Healthy Adult Participants
Latest Information Update: 12 Jan 2024
At a glance
- Drugs Psilocybin (Primary)
- Indications Binge-eating disorder; Cancer; Complex regional pain syndromes; Fibromyalgia; Pain
- Focus Adverse reactions
Most Recent Events
- 12 Jan 2024 New trial record
- 08 Jan 2024 According to a TRYP Therapeutics media release, achieving the three predetermined targets of psilocin blood levels in this study and confirming their safety will serve as the basis for dose selection in our planned Phase 2 studies with TRP-8803.
- 08 Jan 2024 According to a TRYP Therapeutics media release, The Company has received approval from the Human Research Ethics Committee (HREC) in Australia to commence the groundbreaking Phase 1 clinical trial of TRP-8803 in healthy human volunteers.